The European Medicines Agency entered the third phase of its plan to keep industry gears moving while the agency prepares for the UK’s exit from the EU, and said it will temporarily reduce or suspend more activities to save resources.
Effective Nov. 1, the agency will temporarily reduce the number of guidelines it will process and pause all non-product meetings of working parties, to mitigate Brexit’s effect on operations and account for anticipated staff losses from its move to Amsterdam.
The agency said product-specific meetings will go on as usual, it will continue work on seven guidelines that address an urgent public health need or are needed for the transition to Brexit, and it will continue to implement new and revised legislation.
[FDANews]